选择患者进行治疗高血压的干预手术
Melvin D Lobo1, Gurvinder Rull1, Manish Saxena1
1William Harvey Research Institute, Barts NIHR Biomedical Research Centre, Queen Mary University of London, London, UK.
脏缩有效治疗高血压,包括耐药病例,患者不能通过药物控制. 然而,在干预之前,必须排除二次高血压.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
背景情况:
- 高血压管理往往需要多式联络方式.
- 干预疗法为控制不佳或药物厌恶的患者提供了替代方案.
研究的目的:
- 审查新兴的高血压干预疗法.
- 评估对脏皮损伤的疗效和适用情况.
主要方法:
- 审查干预策略,包括通过射频,超声波和酒精进行脏剥皮 (RDN).
- 对巴罗反射激活疗法和心脏神经调节的评估.
- 专注于RDN作为欧盟的商业化选择.
主要成果:
- 脏缺血在没有药物治疗的高血压患者和耐药高血压患者中都显示出有效性.
- 对于严重的高血压病例来说,RDN是一种可行的选择.
结论:
- RDN对抗性高血压有效,但对二次形式缺乏证据.
- 对于二次高血压和器官损伤的术前评估至关重要.
- 需要仔细诊断和管理二次高血压.
更多相关视频
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
10:46Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
相关概念视频
Pre-Procedural Guidelines for Assessing Blood Pressure
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure VI: Adjunct Therapies
Coronary Artery Disease V: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
